Editorial commentaries
127 Measuring case complexity in neurological rehabilitation
D Wade

128 Roll on genetics of PARK and Parkinsonism in the developing world
R N Kalaria, R Akinwumi

129 Anticholinergic activity and cognitive decline in Parkinson's disease
S E Starkstein

Epilepsy
130 Awake seizures after pure sleep-related epilepsy: a systematic review and implications for driving law
RH Thomas, WH King, JA Johnston, PEM Smith

136 Individual white matter fractional anisotropy analysis on patients with MRI negative partial epilepsy
T Duning, C Kellinghaus, S Mohammadi, H Schiffhauer, S Keller, E B Ringelstein, S Knecht, M Deppe

Cognition and dementia
140 Standardised measurement of self-awareness deficits in FTD and AD
C Williamson, O Alcantara, J Rothblind, D Cahn-Weiner, B L Miller, H J Rosen

146 The Rehabilitation Complexity Scale version 2: a clinimetric evaluation in patients with severe complex neurodisability
L Turner-Stokes, H Williams, R J Siegert

154 Utility behaviour in frontotemporal dementia
A Glosli, A Dutt

157 Attention deficits in Alzheimer's disease and vascular dementia
B McGuinness, S I Barrett, D Craig, J Lawson, A P Rossmore

Movement disorders
160 Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study
U Ehrt, K Broich, J P Larsen, C Ballard, D Aarsland

166 Genetic screening reveals high frequency of PARK2 mutations and reduced Parkinson expression conferring risk for Parkinsonism in North West India
M Vinish, S Prabhakar, M Khullar, I Verma, A Anand

Stroke and cardiovascular disease
185 MR diffusion and perfusion parameters: relationship to metabolites in acute ischaemic stroke
V Cvero, I Marshall, P A Armitage, M E Bastin, T Carpenter, C S Rivers, M S Dennis, J M Wardlaw

Neurological picture
203 Atherosclerosis in congenital azygous solitary A2 anterior cerebral artery with simultaneous bifrontal infarctions
P K Loh, V K Sharma

Multiple sclerosis
204 Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes
M Di Filippo, V M Anderson, D R Altmann, J K Swanton, G T Plant, A J Thompson, D H Miller
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>209</td>
<td>Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database</td>
<td>W Qiu, J-S Wu, M-N Zhang, T Matsushita, J-i Kira, W M Carroll, F L Mastaglia, A G Kermode</td>
</tr>
<tr>
<td>213</td>
<td>Primary Sjögren syndrome presenting as neuromyelitis optica</td>
<td>M H Rabadi, S Kundu, D Brett, R Padmanabhan</td>
</tr>
<tr>
<td>215</td>
<td>Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: record linkage studies</td>
<td>A F Fois, C J Wotton, D Yeates, M R Turner, M J Goldacre</td>
</tr>
<tr>
<td>222</td>
<td>Upregulation of persistent sodium conductances in familial ALS</td>
<td>S Vucic, M C Kiernan</td>
</tr>
<tr>
<td>228</td>
<td>Late-onset Huntington disease with intermediate CAG repeats: true or false?</td>
<td>J L Groen, R MA de Bie, E MJ Foncke, R AC Rees, K L Leenders, M AJ Tijssen</td>
</tr>
<tr>
<td>231</td>
<td>Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations</td>
<td>B Wen, T Dai, W Li, Y Zhao, S Liu, C Zhang, H Li, J Wu, D Li, C Yan</td>
</tr>
</tbody>
</table>